The shelf registration follows a recent $56.5 million financing and comes amid an expansion of the firm's commercial operations.
The company said it would use the proceeds of the offering to promote its genetic tests and services, among other things.
The company announced this week the sale of 9,090,909 shares of common stock, which it expects will raise proceeds of roughly $30 million before expenses.
The company is offering approximately 8.8 million shares of common stock at a price of $171 per share.
The company's Luxembourg subsidiary has also extended the offering period for its Patheon purchase to coordinate with regulatory approvals in the EU and Brazil.
The company priced its offering at $1.40 per unit and said it intends to use the proceeds for operations and for other general corporate purposes.
The Gaithersburg, Maryland-based firm intends to use the proceeds for general corporate purposes, including working capital and product development.
The firm said it will offer 25 million units consisting of common stock and common warrants at $.40 per unit.
The company previously said that it planned to publicly offer up to $10 million in stocks and warrants. It has not priced the offering yet.
Great Basin plans to use the proceeds for R&D, sales and marketing expenses, the redemption of certain notes, and general corporate purposes.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.